Lipocine's Postpartum Depression Drug Fails; AstraZeneca Claims Liver Cancer Win
Lipocine reported top‑line Phase 3 data for its postpartum depression candidate LPCN‑1154, revealing no statistically significant improvement over placebo and prompting a 77% plunge in its shares. The Utah‑based biotech’s safety profile was acceptable, but efficacy shortfalls undermine its commercial prospects. Meanwhile, AstraZeneca announced encouraging results from a liver cancer trial, suggesting a potential new indication for its oncology portfolio. Both developments highlight divergent outcomes in biotech pipelines this week.
HNSCC Market Is Expected to Reach to $4.5bn Across 8MM by 2034
GlobalData projects the head and neck squamous cell carcinoma (HNSCC) therapeutics market to grow from $2.0 bn in 2024 to $4.5 bn by 2034, reflecting an 8.4% compound annual growth rate. Immune checkpoint inhibitors (ICIs) dominate, accounting for 69% of 2024 sales...
Pfizer Halts COVID Shot Trial Because They Can’t Find Enough Test Subjects Willing to Take Another Booster Shot
Pfizer and BioNTech have halted a large U.S. clinical trial of an updated COVID‑19 booster after failing to enroll enough healthy adults aged 50‑64. The study required tens of thousands of participants, but recruitment stalled amid a sharp decline in...
Asundexian
Bayer’s oral factor XIa inhibitor asundexian (BAY 2433334) has delivered positive Phase 3 data in the OCEANIC‑STROKE trial, positioning it as a potential first‑in‑class therapy for secondary stroke prevention. The drug aims to block pathological clot formation while minimizing the bleeding complications common...
New Opioid Painkiller Has Surprisingly Few Side Effects
Scientists have identified a new opioid, N-desethyl‑fluornitrazene (DFNZ), derived from the long‑abandoned nitazene class, that delivers strong pain relief in rodents without causing respiratory depression or high addiction potential. The molecule acts as a μ‑opioid‑receptor superagonist yet exits the brain...
STAT+: Lilly’s Obesity Pill Enters the Oral GLP-1 Game, Novo Responds
The FDA approved Eli Lilly’s oral GLP‑1 obesity pill orforglipron, marking the first FDA‑cleared oral weight‑loss drug. The approval puts Lilly into direct competition with Novo Nordisk, which is developing its own oral GLP‑1 candidate. Simultaneously, a draft Trump administration order could...
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Shionogi completed a $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding an approved ALS treatment to its portfolio. The deal transfers all intellectual property, sales rights and the existing commercial team, delivering an estimated $700 million in annual...
FDA Approves Eli Lilly’s Foundayo Pill as NHS Expands Wegovy to Over 1 Million Heart Patients
The FDA gave fast‑track approval to Eli Lilly’s oral GLP‑1 obesity drug Foundayo, and the UK’s NHS announced a rollout of semaglutide (Wegovy) to over 1 million adults with prior heart attacks or strokes. Both moves broaden the therapeutic reach of GLP‑1...
Harvard Launches Trial to Test Psychedelic Coaching Boost for Ketamine Depression Therapy
Harvard investigators at Massachusetts General Hospital have started a randomized clinical trial to evaluate whether adding psychedelic coaching to FDA‑approved ketamine infusions improves outcomes for patients with treatment‑resistant depression. The study aims to settle a growing debate over the role...
UK NHS to Offer Wegovy to 1.2 Million Heart Patients, Expanding GLP‑1 Use Beyond Obesity
The UK’s National Health Service will prescribe semaglutide (Wegovy) to about 1.2 million adults who have had a heart attack or stroke and have a BMI of 27 or higher. The move follows NICE’s recommendation and a cost‑effective deal with Novo...
NUS Unveils Wearable Sensor that Tracks Fatigue and Stress with Clinical-Grade Accuracy
The National University of Singapore announced a wearable sensor that continuously monitors fatigue and stress, achieving 93% peak‑detection accuracy and ISO‑grade signal quality. The device, built on a metahydrogel platform with AI denoising, could give meditation practitioners a reliable physiological...
Johns Hopkins Uses Digital Heart Twins to Boost VT Ablation Success to 80%
Researchers at Johns Hopkins University employed patient‑specific digital heart‑twin models to guide ventricular tachycardia ablations in ten patients, achieving arrhythmia‑free outcomes in eight and only brief episodes in two – a success rate well above the typical 60%. The FDA‑approved...
Harbin Institute of Technology Demonstrates DNA Nanorobots that Capture SARS‑CoV‑2
Scientists from the Harbin Institute of Technology have built DNA‑based nanorobots that can locate and bind SARS‑CoV‑2 virus particles in vitro. The machines, only a few dozen nanometers across, use strand‑displacement chemistry to change shape and deliver drugs directly to...
Analytics that Matter- How LC and MALS Drive Biosimilar Success
The FDA released draft guidance in October 2025 that reshapes biosimilar development by emphasizing analytical data. The guidance suggests that robust analytical comparability can replace or reduce comparative efficacy studies. It calls for comprehensive analytical packages using orthogonal techniques such as...
The Rollercoaster Ride Stopps and Danish IO Biotech Goes Bust
Copenhagen‑based IO Biotech, a cancer immunotherapy firm, saw its flagship melanoma vaccine Cylembio miss the primary endpoint in a Phase III trial, prompting the FDA to advise against filing for approval. The regulatory setback left the company with insufficient runway, as...
From Biological Principles to AI and Back Again
The EMBL‑EMBO AI and Biology symposium in March 2026 highlighted a paradigm shift: artificial intelligence is moving from pattern‑matching to uncovering causal mechanisms in life sciences. Researchers showcased interpretable deep‑learning models for RNA splicing, probed AlphaFold2’s confidence, and revealed hidden...
Merck Receives the EC Approval for Keytruda, Plus CT ± Avastin to Treat PD-L1+ Pt-Resistant Ovarian Carcinoma
The European Commission has granted approval for Merck’s Keytruda (pembrolizumab) combined with paclitaxel, with or without Avastin, to treat PD‑L1‑positive, platinum‑resistant ovarian, fallopian‑tube or primary peritoneal carcinoma. The indication covers adults who have received one or two prior systemic regimens...
Bovine Serum Albumin Crosslinked Hydrogels with Enhanced Mechanical Properties for Skin Bioelectronics
A new protein‑crosslinking method incorporates modified bovine serum albumin (BSA) into hydrogel networks, delivering ultra‑stretchable, strongly adhesive, and conductive gels. Dual physical‑chemical bonds and the protein’s spring‑like secondary structures dramatically improve mechanical strength and energy dissipation. The abundant functional groups...
Creatine Plus Probiotic Eases Depression via Gut‑brain Energy Boost
1/2) New placebo-controlled human randomized controlled trial finds creatine + a specific probiotic is effective in treating depression. The mechanism is fascinating, involving the probiotic increasing creatine transporters in the gut, leading to increased brain energy metabolism. If you're passionate about this...
A New Implant Aims to Rewire the Brain to Help Stroke Patients
Epia Neuro, a San Francisco startup, unveiled a brain‑computer interface paired with a motorized glove to restore hand function in stroke patients. The disk‑shaped implant sits under the skull, captures neural intent from undamaged brain regions, and translates it via...
Biocytogen and Sihuan Pharmaceutical Partner to Discover Novel Therapeutics in Multiple Indications
Biocytogen and China’s Sihuan Pharmaceutical have signed a strategic partnership to co‑develop novel antibody therapeutics across several disease areas, including obesity. The deal merges Biocytogen’s fully human antibody discovery platform—featuring target‑humanized mouse models, in‑vivo efficacy systems, and an AI‑driven sequence...
Sinclair Reverses Mouse Infertility, Challenges Menopause Limits
David Sinclair's lab just reversed infertility in mice that had been infertile for 6 months. They took 16-month-old mice, the equivalent of a woman well past menopause, and made them produce offspring again. The belief has always been that mammals run out...
ACC 2026: Meta-Analysis Supports CagriSema as Superior First-Line Therapy in Obesity
At the ACC 2026 meeting, a Bayesian network meta‑analysis of 2,803 overweight and obese adults showed that the fixed‑dose combination CagriSema outperformed its components, cagrilintide and semaglutide 2.4 mg, across all efficacy measures. CagriSema delivered the greatest absolute and percent weight...
SpectraCell Packages Longevity, Early Disease Detection in One Kit
SpectraCell Laboratories introduced Baseline Nexus, a bundled diagnostic kit that merges four flagship tests—micronutrient profiling, lipoprotein particle analysis, telomere length measurement, and MTHFR genotyping—into a single service. The package aims to reveal hidden nutrient deficiencies, cardiovascular risk, biological aging, and...
Rhythm Posts First FDA Approval for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity, covering adults and children aged four and older. The decision follows the Phase 3 TRANSCEND trial, which demonstrated an 18.4% mean BMI reduction versus placebo...
AstraZeneca Reports the P-III (EMERALD-3) Trial Data on Imfinzi Combination + TACE in Unresectable Hepatocellular Carcinoma
AstraZeneca presented interim data from its Phase III EMERALD-3 trial, evaluating a single priming dose of Imjudo (300 mg) plus Imfinzi (1500 mg) followed by quarterly Imfinzi and transarterial chemoembolisation (TACE) with or without lenvatinib in 760 patients with unresectable hepatocellular carcinoma...
Case Western Study Finds NMN and NR May Shield Pancreatic Cancer Cells From Chemotherapy
Researchers at Case Western Reserve University reported that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can help pancreatic cancer cells survive standard chemotherapy, raising safety concerns for patients and the biohacking community that widely uses these supplements.
NR0B2 Is Protective of Cartilage, But Expression Decreases as Osteoarthritis Progresses
Researchers identified the orphan nuclear receptor NR0B2 (also known as SHP) as a protective factor in cartilage, with its expression markedly reduced in osteoarthritic tissue. In male mice, global or chondrocyte‑specific deletion of Nr0b2 worsened pain and joint damage after...
FDA Grants Fast Track Approval to Eli Lilly's $149‑$349 Daily Weight‑Loss Pill Foundayo
The U.S. Food and Drug Administration has granted expedited approval to Eli Lilly's oral GLP‑1 weight‑loss pill, Foundayo, priced between $149 and $349 per month. The decision pits Lilly against Novo Nordisk’s injectable and oral options and could reshape obesity...
Pharma Pulse: Foundayo’s FDA Approval and the Strategic Risk of Pharmacy Data Consolidation
Eli Lilly’s Foundayo became the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing in a record 50 days. It is the only GLP‑1 weight‑loss pill that can be taken without food or water restrictions, aiming to...
Scientists Cured Type 1 Diabetes in Mice by Creating a Blended Immune System
Scientists have cured type 1 diabetes in mice by creating a blended, or chimeric, immune system that tolerates transplanted insulin‑producing cells without lifelong immunosuppression. The protocol combines donor bone‑marrow stem cells, islet cells, low‑dose radiation, antibodies and the drug baricitinib, allowing...
What Will Approval of Foundayo GLP-1 Tablets Bring?
The FDA has approved Foundayo (orforglipron), the first non‑peptide oral GLP‑1 tablet for obesity. As a small‑molecule drug, it sidesteps the manufacturing complexities that plagued peptide injectables like semaglutide and tirzepatide. Daily oral dosing promises easier adherence compared with weekly...
Actinogen Treats First Patient in XanaMIA Trial for Alzheimer’s
Actinogen Medical has begun treating the first participant in the open‑label extension (OLE) of its Phase IIb/III XanaMIA trial for Alzheimer’s disease. The OLE allows eligible U.S. and Australian subjects to receive Xanamem 10 mg daily for up to 25 months, collecting...
Cogent Biosciences Reports US FDA’s NDA Submission of Bezuclastinib for Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences announced that the U.S. FDA has received a New Drug Application for bezuclastinib under the Real-Time Oncology Review program, targeting gastrointestinal stromal tumor patients who have progressed after imatinib. The Phase III PEAK trial, comparing bezuclastinib plus sunitinib to...
All G Clears FDA Review for Precision-Fermented Lactoferrin
All G, backed by Agronomics, received a FDA “no questions” GRAS letter for its precision‑fermented bovine lactoferrin, LFX. The approval confirms the recombinant protein’s safety and clears the path for US commercialization in functional foods, dietary supplements, and early‑life nutrition. LFX...
Radiopharma Firm Secures $85M to Expand Domestic Production of Radioisotopes
Indiana‑based SpectronRx announced an $85 million investment from OrbiMed to expand its U.S. radioisotope production capacity. The funding will support construction of a 150,000‑square‑foot facility on its Grissom Aeroplex campus, adding to existing 200,000‑square‑foot manufacturing space and bringing total global capacity...
Nionyx Bio’s Kidney Gene Therapy Wins the 2026 BIO-Europe Spring Startup Spotlight
Nionyx Bio, led by CEO Magdalena Tyrpien, captured first place in the 2026 BIO‑Europe Spring Startup Spotlight in Lisbon. The company focuses on a proprietary adeno‑associated virus (AAV) capsid platform paired with a Kidney Atlas to deliver gene therapies for...
Annovis Publishes Historical Review of Buntanetap
Annovis released a historical review of its investigational drug Buntanetap in The Scientist, charting its evolution from a 19th‑century execution poison to a modern candidate for Alzheimer’s and Parkinson’s disease. The article details discovery, mechanism elucidation, chemical optimization, and progression...
New FDA‑approved Oral Weight‑loss Pill Expands Patient Options
So… hot off the press: a NEW weight loss PILL just got FDA approved. We’ve had oral (non-injectable) GLP-1s before — but this is one of the first specifically for weight management. When it reaches Malaysia, it could significantly increase demand...
Collaboration Between Bioinformaticians and Wet Biologists Drives Science
🧵The most underrated superpower in science: Bioinformaticians and wet biologists working together. Here’s why it matters. https://t.co/PRuGiq6CbV
I-Lumen Receives FDA IDE to Start US I-SIGHT2 Enrollment
I‑Lumen announced that the U.S. Food and Drug Administration has granted an Investigational Device Exemption (IDE) for its i‑SIGHT2 clinical study. The clearance allows the company to begin enrolling participants in the United States to evaluate its breath‑based metabolic monitoring...
BeamTx's Risto‑cel Shows Promising Phase
1/@BeamTx announced the publication of clinical data from its Phase 1/2 BEACON clinical trial evaluating risto-cel - formerly known as $BEAM-101 for the treatment of sickle cell disease (SCD). The data was presented at #ASH25 🧵👇 & was published in...
Patients Maintain Weight Loss After Discontinuing GLP‑1s, Epic Shows
Interesting data from Epic medical records - suggests that for many patients in the "real world", they are able to keep the weight off after stopping GLP1s... https://t.co/dHfYdG6rEX #EpicResearch
JenaValve Launches Trilogy Transcatheter Heart Valve System in the US to Treat Symptomatic, Severe Aortic Regurgitation (ssAR)
JenaValve has begun commercializing its Trilogy Transcatheter Heart Valve (THV) system in the United States, becoming the first FDA‑approved transcatheter device for symptomatic, severe aortic regurgitation (ssAR). The valve uses radiopaque locators that attach directly to native leaflets, enabling stable...
Young Plasma Boosts Antioxidant Defense, Preserves Aged Lungs
Young plasma transfer enhances antioxidant defense and preserves structural integrity in aged lung tissue https://t.co/v1lR1EyCKv https://t.co/ZYJu1qNsDl
Biotech Gains as Pharma Approval Success Diverges
Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus
Eli Lilly Reports US FDA Approval of Foundayo (Orforglipron) for Weight Loss
The U.S. FDA has approved Foundayo (orforglipron), Lilly’s first oral GLP‑1 pill, for obese or overweight adults with weight‑related health issues, to launch via LillyDirect on April 6, 2026. In the ATTAIN‑1 trial the highest dose produced an average 27.3‑lb (12.4%) weight...
Clinicians Invited to Join Controlled MDMA Study at UCL
Clinicians: UCL and Drug Science invite you to contribute to a controlled exploration of MDMA’s psychological effects. Eligible participants will undergo two medically supervised sessions at UCL. This work aims to build a psychoanalytically grounded model of its therapeutic action....
China’s Clinical Trials Surge, Outpacing US and Europe
In 2010, China accounted for fewer than 8% of global clinical trials. By 2020, it had surpassed both US & Europe in registered trials. By 2024, China was initiating more than 5,000 clinical trials a year — a more than...
Injectable Satellite Livers May Replace Transplants
Injectable “satellite livers” could offer an alternative to liver transplantation by Anne Trafton @MIT Learn more: https://t.co/HZg5qoXutb #HealthTech #ArtificialIntelligence #MachineLearning https://t.co/V4W3VUpDbw